phosphatidyl-L-serineWhat was measured
Measured, with no finding
213 endpoints
Show what was measuredHide what was measured
cognitive measures in probable Alzheimer's disease (instruments not named in the abstract)
increases
Not recorded as a finding: this platform holds no node for the endpoint
Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo.
PMID 1609044 · one of two readings recorded this
cognitive measures, treatment-group differences by severity
increases
Differences between treatment groups were most apparent among patients with less severe cognitive impairment
PMID 1609044 · one of two readings recorded this
cognitive measures
increases
Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo
PMID 1609044 · one of two readings recorded this
unnamed cognitive measures in probable Alzheimer's disease, 12 weeks, BC-PS 100 mg t.i.d. vs placebo
increases
Not recorded as a finding: no estimate is reported anywhere
Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo.
PMID 1609044 · one of two readings recorded this
clinical global improvement rating; GBS dementia rating scale; P300 latency; 16-channel EEG power mapping
increases
Not recorded as a finding: this platform holds no node for the endpoint
Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one.
PMID 1633433 · one of two readings recorded this
clinical global improvement rating, number of patients improving, phase one of crossover; also GBS dementia rating scale, psychometric tests, P300 latency, 16-channel EEG power
increases
Not recorded as a finding: this platform holds no node for the endpoint
Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one.
PMID 1633433 · one of two readings recorded this
clinical global improvement ratings
increases
Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one
PMID 1633433 · one of two readings recorded this
EEG power at baseline versus healthy controls
increases
16-channel EEG mapping findings indicated that the patients initially showed higher power values in all frequency bands (except alpha), when compared to a younger, healthy control group
PMID 1633433 · one of two readings recorded this
EEG power values
decreases
BC-PS reduced the higher power values compared to placebo, shifting EEG power more towards the normal level
PMID 1633433 · one of two readings recorded this
GBS dementia rating scale
no effect
There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency
PMID 1633433 · one of two readings recorded this
P300-latency
no effect
There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency
PMID 1633433 · one of two readings recorded this
psychometric tests
no effect
There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency
PMID 1633433 · one of two readings recorded this
exercise time to exhaustion at 85% VO2max after three 10-min stages at 45, 55 and 65% VO2max, cycling, 750 mg/day soybean PS for 10 days versus placebo, 14 active men
increases, PS 7:51 +/- 1:36 to 9:51 +/- 1:42 min:s; placebo 8:09 +/- 0:54 to 8:02 +/- 0:54 min:s, p = 0.001
Not recorded as a finding: the result compares a group with itself, not with a control
The exercise time to exhaustion in PS increased following supplementation (7:51 +/- 1:36 to 9:51 +/- 1:42 min:s, P = 0.001), whereas P remained unchanged (8:09 +/- 0:54 to 8:02 +/- 0:54 min:s, P = 0.670).
PMID 16394955 · one of two readings recorded this
exercise time to exhaustion at 85% VO2max after three 10-min stages at 45, 55 and 65% VO2max on a cycle ergometer, 750 mg/day soybean PS for 10 days versus placebo
significant supplementation effect on time to exhaustion, P = 0.005, p = 0.005
Not recorded as a finding: the direction is carried only as a signed number
The main finding of this study was that supplementation had a significant effect on exercise time to exhaustion at 85% VO2max (P = 0.005).
PMID 16394955 · one of two readings recorded this
exercise time to exhaustion at 85% VO2max, pre to post supplementation
increases, p = 0.001, n = 14
The exercise time to exhaustion in PS increased following supplementation (7:51 +/- 1:36 to 9:51 +/- 1:42 min:s, P = 0.001)
PMID 16394955 · one of two readings recorded this
exercise time to exhaustion at 85% VO2max, pre to post supplementation
no effect, p = 0.67, n = 14
whereas P remained unchanged (8:09 +/- 0:54 to 8:02 +/- 0:54 min:s, P = 0.670)
PMID 16394955 · one of two readings recorded this
exercise time to exhaustion at 85% VO2max (supplementation effect)
increases, p = 0.005, n = 14
The main finding of this study was that supplementation had a significant effect on exercise time to exhaustion at 85% VO2max (P = 0.005)
PMID 16394955 · one of two readings recorded this
feeling states
no effect, n = 14
Supplementation did not significantly affect oxygen kinetic mean response times (MRT(on) and MRT(off)), serum cortisol concentrations, substrate oxidation, and feeling states during the trial
PMID 16394955 · one of two readings recorded this
oxygen kinetic mean response times (MRT on and MRT off)
no effect, n = 14
Supplementation did not significantly affect oxygen kinetic mean response times (MRT(on) and MRT(off)), serum cortisol concentrations, substrate oxidation, and feeling states during the trial
PMID 16394955 · one of two readings recorded this
serum cortisol concentration
no effect, n = 14
Supplementation did not significantly affect oxygen kinetic mean response times (MRT(on) and MRT(off)), serum cortisol concentrations, substrate oxidation, and feeling states during the trial
PMID 16394955 · one of two readings recorded this
substrate oxidation
no effect, n = 14
Supplementation did not significantly affect oxygen kinetic mean response times (MRT(on) and MRT(off)), serum cortisol concentrations, substrate oxidation, and feeling states during the trial
PMID 16394955 · one of two readings recorded this
interleukin-6 concentration
increases, p = 0.001, n = 8
Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)
PMID 16960523 · one of two readings recorded this
creatine kinase activity
increases, p = 0.001, n = 8
Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)
PMID 16960523 · one of two readings recorded this
lipid hydroperoxide concentration
increases, p = 0.01, n = 8
Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)
PMID 16960523 · one of two readings recorded this
myoglobin concentration
increases, p = 0.001, n = 8
Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)
PMID 16960523 · one of two readings recorded this
perceived soreness
increases, p = 0.05, n = 8
Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)
PMID 16960523 · one of two readings recorded this
soreness, muscle damage, inflammation and oxidative stress responses to downhill running
no effect, n = 8
However, supplementation did not significantly attenuate these responses
PMID 16960523 · one of two readings recorded this
age at pre-test
n = 20
Age (years) | 33.1 ± 7.5 | 31.4 ± 4.5
PMID 18053194 · one of two readings recorded this
body weight at pre-test
n = 20
Bodyweight (kg) | 77.6 ± 7.8 | 84.6 ± 13.2
PMID 18053194 · one of two readings recorded this
golf handicap at pre-test
n = 20
Handicap | 26.8 ± 7.5 | 27.8 ± 8.0
PMID 18053194 · one of two readings recorded this
golf performance as number of good ball flights out of 20 tee-offs rated by a golf trainer; also mean heart rate by Polar monitor and perceived stress on a 1-10 VAS during tee-off
increases, good ball flights pre-test 8.3 to post-test 10.1 on PS versus 7.8 to 7.9 on placebo; within-group p<0.05 for PS
Not recorded as a finding: this platform holds no node for the endpoint
Phosphatidylserine supplementation significantly increased (<0.05) ball flight accuracy (mean number of good ball flights: pre-test 8.3 ± 3.5, post-test 10.1 ± 3.0), whereas placebo intake (mean number of good ball flights: pre-test 7.8 ± 2.4, post-test 7.9 ± 3.6) had no effect on performance (see figure).
PMID 18053194 · one of two readings recorded this
height at pre-test
n = 20
Height (cm) | 181.3 ± 8.8 | 183.6 ± 5.0
PMID 18053194 · one of two readings recorded this
inter-rater reliability of ball flight rating (contingency coefficient)
p = 0.001
The relationship of two expert ratings was significant (p < 0.001) with a contingency coefficient of C = 0.673
PMID 18053194 · one of two readings recorded this
mean heart rate during tee-off series
no effect, n = 10
Phosphatidylserine (mean heart rate: pre-test 113.8 ± 17.7 bpm, post-test 111.3 ± 20.2 bpm) and placebo supplementation (mean heart rate: pre-test 114.3 ± 11.7 bpm, post-test 111.1 ± 15.7 bpm) did not significantly lower mean heart rate during the series of tee-offs
PMID 18053194 · one of two readings recorded this
mean heart rate during tee-off series
no effect, n = 10
Phosphatidylserine (mean heart rate: pre-test 113.8 ± 17.7 bpm, post-test 111.3 ± 20.2 bpm) and placebo supplementation (mean heart rate: pre-test 114.3 ± 11.7 bpm, post-test 111.1 ± 15.7 bpm) did not significantly lower mean heart rate during the series of tee-offs
PMID 18053194 · one of two readings recorded this
number of good ball flights out of 20 tee-offs, rated by a golf trainer; perceived stress on a 1-10 VAS; mean heart rate during tee-offs, Polar S810
increases, good ball flights, PS pre-test 8.3 +/- 3.5, post-test 10.1 +/- 3.0; placebo 7.8 +/- 2.4 to 7.9 +/- 3.6
Not recorded as a finding: this platform holds no node for the endpoint
Phosphatidylserine supplementation significantly increased (<0.05) ball flight accuracy (mean number of good ball flights: pre-test 8.3 ± 3.5, post-test 10.1 ± 3.0), whereas placebo intake (mean number of good ball flights: pre-test 7.8 ± 2.4, post-test 7.9 ± 3.6) had no effect on performance (see figure).
PMID 18053194 · one of two readings recorded this
number of good ball flights out of 20 tee-offs
increases, p = 0.05, n = 10
Phosphatidylserine supplementation significantly increased (<0.05) ball flight accuracy (mean number of good ball flights: pre-test 8.3 ± 3.5, post-test 10.1 ± 3.0)
PMID 18053194 · one of two readings recorded this
number of good ball flights out of 20 tee-offs
no effect, n = 10
whereas placebo intake (mean number of good ball flights: pre-test 7.8 ± 2.4, post-test 7.9 ± 3.6) had no effect on performance
PMID 18053194 · one of two readings recorded this
perceived stress during tee-off (VAS)
decreases, p = 0.07, n = 10
Phosphatidylserine intake showed a trend towards improving perceived stress levels during tee-off on a driving range (mean: pre-test 5.8 ± 2.0, post-test 4.0 ± 2.0, p = 0.07)
PMID 18053194 · one of two readings recorded this
perceived stress during tee-off (VAS)
no effect, n = 10
whereas perceived stress levels remained unchanged in the placebo group (mean: pre-test: 5.1 ± 2.0, post-test: 5.1 ± 3.1)
PMID 18053194 · one of two readings recorded this
Beta-1 EEG power, right frontal (F8)
decreases, p = 0.05, n = 16
The main finding of the study was that chronic supplementation of phosphatidylserine significantly decreases Beta-1 power in right hemispheric frontal brain regions (F8; P < 0.05) before and after induced stress
PMID 18616866 · one of two readings recorded this
EEG band power (Theta, Alpha-1, Alpha-2, Beta-1, Beta-2) at 17 electrodes by fast Fourier transform, before and after induced mental stress, 16 healthy subjects
decreases
Not recorded as a finding: this platform holds no node for the endpoint
The main finding of the study was that chronic supplementation of phosphatidylserine significantly decreases Beta-1 power in right hemispheric frontal brain regions (F8; P < 0.05) before and after induced stress.
PMID 18616866 · one of two readings recorded this
EEG Beta-1 power at electrode F8 (right frontal) before and after induced stress, FFT of 17-electrode EEG, PS versus placebo for 42 days
decreases, significant decrease in Beta-1 power, F8, P < 0.05
Not recorded as a finding: this platform holds no node for the endpoint
The main finding of the study was that chronic supplementation of phosphatidylserine significantly decreases Beta-1 power in right hemispheric frontal brain regions (F8; P < 0.05) before and after induced stress.
PMID 18616866 · one of two readings recorded this
blood glucose level
modulates
Although a significant difference in blood glucose level at 6 month between placebo and PS100 group appeared, such difference was not observed at higher dose (PS300)
PMID 21103034 · one of two readings recorded this
blood glucose level
no effect
Although a significant difference in blood glucose level at 6 month between placebo and PS100 group appeared, such difference was not observed at higher dose (PS300)
PMID 21103034 · one of two readings recorded this
Everyday Memory Checklist score
no effect
Both GDS and EMC scores showed a gradual decrease in all 3 groups, but there was no significant difference among the groups at any evaluation point
PMID 21103034 · one of two readings recorded this
everyday memory on the Rivermead Behavioural Memory Test standardized profile score (primary outcome), with HDS-R and MMSE delayed word recall subtests, in elderly Japanese with memory complaints, Soy-PS 100 or 300 mg/day versus placebo for 6 months
no effect, no difference between Soy-PS and placebo at any evaluation point
Not recorded as a finding: this platform holds no node for the endpoint
The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point.
PMID 21103034 · one of two readings recorded this
Geriatric Depression Scale score
no effect
Both GDS and EMC scores showed a gradual decrease in all 3 groups, but there was no significant difference among the groups at any evaluation point
PMID 21103034 · one of two readings recorded this
HDS-R delayed word recall (DWR) subtest, low-score subgroup, versus placebo
increases, p = 0.09
The scores of Soy-PS treated groups increased significantly against the baseline, and there were significant differences between placebo and both Soy-PS groups after 3 months of follow-up (p<0.05 for 300PS, p = 0.09 for 100PS)
PMID 21103034 · one of two readings recorded this
HDS-R delayed word recall (DWR) subtest, low-score subgroup, versus placebo
increases, p = 0.05
The scores of Soy-PS treated groups increased significantly against the baseline, and there were significant differences between placebo and both Soy-PS groups after 3 months of follow-up (p<0.05 for 300PS, p = 0.09 for 100PS)
PMID 21103034 · one of two readings recorded this
HDS-R other subtests, low-score subgroup
no effect
In fact, there were no significant changes in other subtest scores of HDS-R (data not shown)
PMID 21103034 · one of two readings recorded this
HDS-R total score, after 3-month follow-up
no effect
after the 3-month follow-up period, the score of the placebo group dropped back to its baseline score, while the scores of 100PS and 300PS groups were both maintained at a high level
PMID 21103034 · one of two readings recorded this
HDS-R total score, after 3-month follow-up
increases
after the 3-month follow-up period, the score of the placebo group dropped back to its baseline score, while the scores of 100PS and 300PS groups were both maintained at a high level
PMID 21103034 · one of two readings recorded this
HDS-R total score, during treatment
no effect
The total score of HDS-R increased during the treatment period in all 3 groups, with no significant difference among the groups
PMID 21103034 · one of two readings recorded this
HDS-R total score, high-score subgroup
no effect
In the high-score subgroup, there was almost no score change in the total score of HDS-R throughout the trial
PMID 21103034 · one of two readings recorded this
HDS-R total score, low-score subgroup, change from baseline
increases
In contrast, total score of HDS-R in the low-score subgroup significantly increased against the baseline by Soy-PS treatment
PMID 21103034 · one of two readings recorded this
HDS-R total score, low-score subgroup, versus placebo
increases, p = 0.05
The difference between placebo and 100PS also showed a significant trend (p = 0.05)
PMID 21103034 · one of two readings recorded this
HDS-R total score, low-score subgroup, versus placebo
increases, p = 0.05
There was a significant difference between placebo and 300PS groups after 3 months of follow-up (p<0.05)
PMID 21103034 · one of two readings recorded this
hematological and biological blood parameters
no effect
There was also no clinically significant change in hematological and biological blood parameters in all groups
PMID 21103034 · one of two readings recorded this
MMSE delayed word recall subtest, versus placebo
increases, p = 0.05
The score significantly increased against the baseline only in Soy-PS treated groups, and there were significant differences between placebo and Soy-PS groups (p<0.05 for both 100PS and 300PS)
PMID 21103034 · one of two readings recorded this
MMSE delayed word recall subtest, versus placebo
increases, p = 0.05
The score significantly increased against the baseline only in Soy-PS treated groups, and there were significant differences between placebo and Soy-PS groups (p<0.05 for both 100PS and 300PS)
PMID 21103034 · one of two readings recorded this
RBMT standardized profile score, change from baseline
increases
The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point
PMID 21103034 · one of two readings recorded this
RBMT standardized profile score, change from baseline
increases
The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point
PMID 21103034 · one of two readings recorded this
RBMT standardized profile score, change from baseline
increases
The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point
PMID 21103034 · one of two readings recorded this
RBMT standardized profile score, Soy-PS versus placebo
no effect
The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point
PMID 21103034 · one of two readings recorded this
RBMT, stratified by baseline score, Soy-PS versus placebo
no effect
In stratified analysis based on the subjects’ degree of memory impairment at baseline, there was still no difference between placebo and Soy-PS groups either in the high-score subgroup (RBMT = 19 or more) or the low-score subgroup (RBMT<19)
PMID 21103034 · one of two readings recorded this
Rivermead Behavioural Memory Test standardized profile score; also HDS-R total and delayed word recall subtest, MMSE delayed word recall subtest, EMC, GDS, in elderly Japanese with memory complaints
no effect
Not recorded as a finding: this platform holds no node for the endpoint
The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point.
PMID 21103034 · one of two readings recorded this
urine parameters (glucose, protein, occult blood, pH)
no effect
Vital signs (Table 4) and urine parameters (glucose, protein, occult blood and pH; data not shown) didn’t show any significant changes
PMID 21103034 · one of two readings recorded this
vital signs
no effect
Vital signs (Table 4) and urine parameters (glucose, protein, occult blood and pH; data not shown) didn’t show any significant changes
PMID 21103034 · one of two readings recorded this
AD (attention deficit) symptoms
p = 0.01, n = 36
PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)
PMID 23495677 · one of two readings recorded this
ADHD symptoms by DSM-IV-TR; short-term auditory memory on the WISC Digit Span Test; GO/NO GO visual-stimulus task performance, children aged 4-14
Not recorded as a finding: this platform holds no node for the endpoint
PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05).
PMID 23495677 · one of two readings recorded this
ADHD symptoms (DSM-IV-TR)
p = 0.01, n = 36
PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)
PMID 23495677 · one of two readings recorded this
HD (hyperactivity) symptoms
p = 0.01, n = 36
PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)
PMID 23495677 · one of two readings recorded this
inattention and impulsivity
p = 0.05, n = 36
PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)
PMID 23495677 · one of two readings recorded this
inattention (differentiation and reverse differentiation)
p = 0.05, n = 36
PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)
PMID 23495677 · one of two readings recorded this
other measurements (non-significant)
no effect, n = 36
No significant differences were observed in other measurements and in the placebo group
PMID 23495677 · one of two readings recorded this
short-term auditory memory on the WISC Digit Span Test, ADHD symptoms by DSM-IV-TR, and GO/NO GO visual task performance in children aged 4-14, PS 200 mg/day versus placebo for 2 months
increases, significant improvements in ADHD, AD and HD (P < 0.01) and short-term auditory memory (P < 0.05)
Not recorded as a finding: a node exists but the paper states a different instrument or population
PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05).
PMID 23495677 · one of two readings recorded this
short-term auditory memory
increases, p = 0.05, n = 36
PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)
PMID 23495677 · one of two readings recorded this
hyperactivity-impulsivity
no effect, p = 0.09, n = 216
The effects of phosphatidylserine on overall symptoms of ADHD (ES 0.76; 95% CI: -0.07 to 1.60; p = 0.07) and hyperactivity-impulsivity (ES 0.24; 95% CI: -0.04 to 0.53; p = 0.09) were not statistically significant
PMID 33539192 · one of two readings recorded this
overall symptoms of ADHD
no effect, p = 0.07, n = 216
The effects of phosphatidylserine on overall symptoms of ADHD (ES 0.76; 95% CI: -0.07 to 1.60; p = 0.07) and hyperactivity-impulsivity (ES 0.24; 95% CI: -0.04 to 0.53; p = 0.09) were not statistically significant
PMID 33539192 · one of two readings recorded this
symptoms of inattention in children with ADHD, pooled standardized mean difference across trials
ES 0.36; 95% CI: 0.07 to 0.64, p = 0.01
Not recorded as a finding: this platform holds no node for the endpoint
Results of the meta-analysis showed a statistically significant effect of 200-300 mg/day of phosphatidylserine on symptoms of inattention relative to placebo (effect size [ES] 0.36; 95% CI: 0.07 to 0.64; p = 0.01).
PMID 33539192 · one of two readings recorded this
symptoms of inattention, overall ADHD symptoms and hyperactivity-impulsivity in children with ADHD, pooled effect size across rating instruments
ES 0.36; 95% CI: 0.07 to 0.64, p = 0.01
Not recorded as a finding: this platform holds no node for the endpoint
Results of the meta-analysis showed a statistically significant effect of 200-300 mg/day of phosphatidylserine on symptoms of inattention relative to placebo (effect size [ES] 0.36; 95% CI: 0.07 to 0.64; p = 0.01).
PMID 33539192 · one of two readings recorded this
symptoms of inattention
decreases, p = 0.01, n = 216
Results of the meta-analysis showed a statistically significant effect of 200-300 mg/day of phosphatidylserine on symptoms of inattention relative to placebo (effect size [ES] 0.36; 95% CI: 0.07 to 0.64; p = 0.01)
PMID 33539192 · one of two readings recorded this
behavioural rating on the Peri Scale (original geriatric-unit scale) and Crichton Scale; circle crossing test
increases
Not recorded as a finding: this platform holds no node for the endpoint
The results indicated a trend toward improvement in the BC-PS treated patients and an analysis of covariance showed a significant (p less than 0.05) treatment effect on the Peri Scale.
PMID 3518329 · one of two readings recorded this
behavioural rating on the Peri Scale (original geriatric-unit scale); Crichton Scale; circle crossing test; hospitalized demented patients, BS-PS 3 x 100 mg vs placebo, six weeks
Not recorded as a finding: this platform holds no node for the endpoint
The results indicated a trend toward improvement in the BC-PS treated patients and an analysis of covariance showed a significant (p less than 0.05) treatment effect on the Peri Scale.
PMID 3518329 · one of two readings recorded this
overall patient rating (Crichton Scale, Peri Scale, circle crossing test)
increases
The results indicated a trend toward improvement in the BC-PS treated patients
PMID 3518329 · one of two readings recorded this
Peri Scale, three weeks after the end of treatment
increases
Here again there was a statistically significant difference in the Peri Scale results
PMID 3518329 · one of two readings recorded this
Peri Scale
increases, p = 0.05, n = 35
an analysis of covariance showed a significant (p less than 0.05) treatment effect on the Peri Scale
PMID 3518329 · one of two readings recorded this
arithmetic testing, similarity test and short-term memory scores; serum ALA, DHA, EPA, acetylcholine, GABA and 5-HT, in older adults with MCI
increases, arithmetic testing beta 0.688 (95% CI 0.103-1.274); similarity test beta 1.070 (95% CI 0.472-1.667); short-term memory beta 0.600 (95% CI 0.399-0.800)
Not recorded as a finding: the intervention held more than the compound
Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800).
PMID 39317299 · one of two readings recorded this
arithmetic testing
increases, n = 190
Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800)
PMID 39317299 · one of two readings recorded this
cognitive subtests (arithmetic, similarity, short-term memory) and serum n-3 PUFAs and neurotransmitters in older adults with mild cognitive impairment at 12 months
increases, arithmetic beta 0.688 (95% CI 0.103-1.274); similarity beta 1.070 (0.472-1.667); short-term memory beta 0.600 (0.399-0.800)
Not recorded as a finding: the intervention held more than the compound
Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800).
PMID 39317299 · one of two readings recorded this
serum 5-HT
increases, n = 190
Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group
PMID 39317299 · one of two readings recorded this
serum acetylcholine
increases, n = 190
Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group
PMID 39317299 · one of two readings recorded this
serum ALA
increases, n = 190
Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group
PMID 39317299 · one of two readings recorded this
serum DHA
increases, n = 190
Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group
PMID 39317299 · one of two readings recorded this
serum EPA
increases, n = 190
Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group
PMID 39317299 · one of two readings recorded this
serum GABA
increases, n = 190
Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group
PMID 39317299 · one of two readings recorded this
short-term memory mediated by serum ALA (average causal mediation effect)
increases, n = 190
And the intervention may improve short-term memory by increasing serum ALA levels (average causal mediation effect = 0.132, 95 % CI, 0.053-0.225) with 19.7 % mediation proportion
PMID 39317299 · one of two readings recorded this
short-term memory
increases, n = 190
Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800)
PMID 39317299 · one of two readings recorded this
similarity test
increases, n = 190
Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800)
PMID 39317299 · one of two readings recorded this
CBCL aggressive behavior, baseline vs month 3
decreases, p = 0.01, n = 28
aggressive | 9.88 ± 5.02 | 7.08 ± 3.56 | 3.22 | 0.004** | 11.61 ± 6.14 | 9.18 ± 5.11 | 2.62 | 0.01*
PMID 41960234 · one of two readings recorded this
CBCL aggressive behavior, baseline vs month 3
decreases, p = 0.004, n = 28
aggressive | 9.88 ± 5.02 | 7.08 ± 3.56 | 3.22 | 0.004** | 11.61 ± 6.14 | 9.18 ± 5.11 | 2.62 | 0.01*
PMID 41960234 · one of two readings recorded this
CBCL aggressive behavior, pre-post change and effect size
decreases, p = 0.05
atomoxetine: M = 2.43, SD = 4.90, corrected p < 0.05, Cohen’s d = 0.50, 95% CI = [0.10, 0.88]
PMID 41960234 · one of two readings recorded this
CBCL aggressive behavior, pre-post change and effect size
decreases, p = 0.05
PS: M = 2.79, SD = 4.24, corrected p < 0.05, Cohen’s d = 0.66, 95% CI = [0.21, 1.1]
PMID 41960234 · one of two readings recorded this
CBCL externalizing, between-group comparison
no effect, p = 0.05
For CBCL externalizing behavior scores, the PS group showed a greater reduction than the atomoxetine group, but the difference was also not statistically significant (p > 0.05)
PMID 41960234 · one of two readings recorded this
CBCL externalizing, pre-post change and effect size
decreases, p = 0.05
M = 2.54, SD = 5.42, corrected p < 0.05, Cohen’s d = 0.47, 95% CI = [0.07, 0.86]
PMID 41960234 · one of two readings recorded this
CBCL externalizing, pre-post change and effect size
decreases, p = 0.05
externalizing: M = 3.38, SD = 5.20, corrected p < 0.05, Cohen’s d = 0.65, 95% CI = [0.20, 1.1]
PMID 41960234 · one of two readings recorded this
CBCL externalizing problems, baseline vs month 3
decreases, p = 0.02, n = 28
Externalizing Problems | 12.29 ± 6.22 | 8.92 ± 4.72 | 3.18 | 0.004** | 14.57 ± 7.54 | 12.04 ± 6.70 | 2.48 | 0.02*
PMID 41960234 · one of two readings recorded this
CBCL externalizing problems, baseline vs month 3
decreases, p = 0.004, n = 28
Externalizing Problems | 12.29 ± 6.22 | 8.92 ± 4.72 | 3.18 | 0.004** | 14.57 ± 7.54 | 12.04 ± 6.70 | 2.48 | 0.02*
PMID 41960234 · one of two readings recorded this
CBCL internalizing, pre-post change and effect size
decreases, p = 0.05
internalizing: M = 1.83, SD = 3.28, corrected p < 0.05, Cohen’s d = 0.56, 95% CI = [0.12, 0.99]
PMID 41960234 · one of two readings recorded this
CBCL internalizing problems, baseline vs month 3
no effect, p = 0.03, n = 28
Internalizing Problems | 6.71 ± 4.70 | 4.88 ± 4.06 | 2.74 | 0.01* | 9.04 ± 3.98 | 6.61 ± 4.79 | 2.26 | 0.03
PMID 41960234 · one of two readings recorded this
CBCL internalizing problems, baseline vs month 3
decreases, p = 0.01, n = 28
Internalizing Problems | 6.71 ± 4.70 | 4.88 ± 4.06 | 2.74 | 0.01* | 9.04 ± 3.98 | 6.61 ± 4.79 | 2.26 | 0.03
PMID 41960234 · one of two readings recorded this
CBCL rule-breaking behavior, baseline vs month 3
no effect, p = 0.13, n = 28
Rule-Breaking | 1.67 ± 0.34 | 1.58 ± 0.32 | 1.69 | 0.11 | 2.96 ± 1.99 | 2.57 ± 1.87 | 1.55 | 0.13
PMID 41960234 · one of two readings recorded this
CBCL rule-breaking behavior, baseline vs month 3
no effect, p = 0.11, n = 28
Rule-Breaking | 1.67 ± 0.34 | 1.58 ± 0.32 | 1.69 | 0.11 | 2.96 ± 1.99 | 2.57 ± 1.87 | 1.55 | 0.13
PMID 41960234 · one of two readings recorded this
core ADHD symptoms on the SNAP-IV parent form (inattention, hyperactivity/impulsivity, total) and internalizing and externalizing problems on the Achenbach CBCL, phosphatidylserine versus atomoxetine
between-group differences not statistically significant (p > 0.05)
Not recorded as a finding: the comparison was against another active treatment
The atomoxetine group exhibited greater reductions in all SNAP-IV dimensions and total scores than the PS group, although the differences were not statistically significant (p > 0.05).
PMID 41960234 · one of two readings recorded this
SNAP-IV attention deficit, pre-post change and effect size
decreases, p = 0.05
attention deficit (M = 0.40, SD = 0.50, corrected p < 0.05, Cohen’s d = 0.80, 95% CI = [0.36, 1.22]
PMID 41960234 · one of two readings recorded this
SNAP-IV attention deficit, pre-post change and effect size
no effect, p = 0.05
attention deficit: M = 0.26, SD = 0.60, Bonferroni-corrected p > 0.05, Cohen’s d = 0.43, 95% CI = [0.04, 0.82]
PMID 41960234 · one of two readings recorded this
SNAP-IV dimensions and total, between-group comparison
no effect, p = 0.05
The atomoxetine group exhibited greater reductions in all SNAP-IV dimensions and total scores than the PS group, although the differences were not statistically significant (p > 0.05)
PMID 41960234 · one of two readings recorded this
SNAP-IV hyperactivity/impulsivity, baseline vs month 3
decreases, p = 0.009, n = 28
Hyperactivity/Impulsivity | 0.77 ± 0.56 | 0.67 ± 0.49 | 1.22 | 0.23 | 1.03 ± 0.64 | 0.77 ± 0.54 | 2.83 | 0.009*
PMID 41960234 · one of two readings recorded this
SNAP-IV hyperactivity/impulsivity, baseline vs month 3
no effect, p = 0.23, n = 28
Hyperactivity/Impulsivity | 0.77 ± 0.56 | 0.67 ± 0.49 | 1.22 | 0.23 | 1.03 ± 0.64 | 0.77 ± 0.54 | 2.83 | 0.009*
PMID 41960234 · one of two readings recorded this
SNAP-IV hyperactivity/impulsivity, pre-post change and effect size
decreases, p = 0.05
hyperactivity/impulsivity (M = 0.26, SD = 0.49, corrected p < 0.05, Cohen’s d = 0.54, 95% CI = [0.13, 0.93]
PMID 41960234 · one of two readings recorded this
SNAP-IV hyperactivity/impulsivity, pre-post change and effect size
no effect, p = 0.05
hyperactivity/impulsivity: M = 0.11, SD = 0.46, corrected p > 0.05, Cohen’s d = 0.23, 95% CI = [-0.15, 0.60]
PMID 41960234 · one of two readings recorded this
SNAP-IV inattention, baseline vs month 3
decreases, n = 28
Inattention | 1.43 ± 0.64 | 1.17 ± 0.48 | 2.30 | 0.03 | 1.59 ± 0.65 | 1.19 ± 0.50 | 4.21 | 0***
PMID 41960234 · one of two readings recorded this
SNAP-IV inattention, baseline vs month 3
unclear, p = 0.03, n = 28
Inattention | 1.43 ± 0.64 | 1.17 ± 0.48 | 2.30 | 0.03 | 1.59 ± 0.65 | 1.19 ± 0.50 | 4.21 | 0***
PMID 41960234 · one of two readings recorded this
SNAP-IV oppositional defiant disorder, baseline vs month 3
no effect, p = 0.1, n = 28
Oppositional Defiant Disorder | 0.70 ± 0.55 | 0.63 ± 0.60 | 0.68 | 0.50 | 0.92 ± 0.61 | 0.79 ± 0.61 | 1.34 | 0.10
PMID 41960234 · one of two readings recorded this
SNAP-IV oppositional defiant disorder, baseline vs month 3
no effect, p = 0.5, n = 28
Oppositional Defiant Disorder | 0.70 ± 0.55 | 0.63 ± 0.60 | 0.68 | 0.50 | 0.92 ± 0.61 | 0.79 ± 0.61 | 1.34 | 0.10
PMID 41960234 · one of two readings recorded this
SNAP-IV total, baseline vs month 3
decreases, p = 0.001, n = 28
Total | 25.36 ± 12.50 | 21.54 ± 10.81 | 1.97 | 0.06 | 30.90 ± 13.19 | 23.89 ± 11.72 | 3.95 | 0.001**
PMID 41960234 · one of two readings recorded this
SNAP-IV total, baseline vs month 3
no effect, p = 0.06, n = 28
Total | 25.36 ± 12.50 | 21.54 ± 10.81 | 1.97 | 0.06 | 30.90 ± 13.19 | 23.89 ± 11.72 | 3.95 | 0.001**
PMID 41960234 · one of two readings recorded this
SNAP-IV total, pre-post change and effect size
decreases, p = 0.05
total scores (M = 7.00, SD = 9.38, corrected p < 0.05, Cohen’s d = 0.75, 95% CI = [0.32, 1.16]
PMID 41960234 · one of two readings recorded this
SNAP-IV total, pre-post change and effect size
no effect, p = 0.05
total: M = 3.82, SD = 10.27, corrected p > 0.05, Cohen’s d = 0.37, 95% CI = [-0.01, 0.75]
PMID 41960234 · one of two readings recorded this
fasting blood glucose
no effect
In our preclinical study in db/db mice, 4wk of PS supplementation did not alter body weight or epididymal fat weight, nor fasting blood glucose
PMID 42312814 · one of two readings recorded this
acetylcholine-induced endothelium-dependent relaxation, aortic rings
increases
PS in db/db mice also abrogated the impaired endothelium-dependent relaxation (i.e., response to ACh) in aortic rings, while endothelium-independent relaxation (i.e., response to SNP) remained unchanged
PMID 42312814 · one of two readings recorded this
ADAM17 activity, ADAM17-overexpressing endothelial cells
decreases
Overexpression of ADAM17 in endothelial cells increased ADAM17 activity compared with control (control virus, Ad-CMV-null), an effect that was also blunted with the treatment of sPS or TAPI-0
PMID 42312814 · one of two readings recorded this
ADAM17 activity, cell-free assay
decreases
We found ADAM17 activity was increased with ADAM17-r in a cell-free assay, which was abrogated with sPS or TAPI-0, an ADAM17 inhibitor
PMID 42312814 · one of two readings recorded this
ADAM17 activity, isolated mesenteric arteries
decreases
Moreover, isolated mesenteric arteries from C57BL/6 mice exposed to sPS or TAPI-0 exhibited a reduction in ADAM17 activity
PMID 42312814 · one of two readings recorded this
ADAM17 activity, naive endothelial cells
decreases
Treatment of naive endothelial cells with sPS or TAPI-0 reduced ADAM17 activity
PMID 42312814 · one of two readings recorded this
ambulatory blood pressure
no effect
There were no changes noted in either group in other cardiovascular outcomes, including brachial artery FMD, AMBP, or leg BF responses to PLM (Table 2)
PMID 42312814 · one of two readings recorded this
aortic alpha-SMA
decreases, p = 0.093
These findings were accompanied by a decrease in α-SMA in the aorta that approached statistical significance (P=0.093, Figure 5G)
PMID 42312814 · one of two readings recorded this
aortic incremental modulus of elasticity (Einc)
decreases
In addition, in vivo aortic PWV, ex vivo aortic stiffness by AFM, and aortic Einc were lower in PS-treated mice, indicative of reduced aortic stiffness
PMID 42312814 · one of two readings recorded this
aortic nitrotyrosine
decreases
Lastly, nitrotyrosine (a marker of oxidative stress) was reduced in aortic rings from PS-fed mice
PMID 42312814 · one of two readings recorded this
baseline blood pressure
no effect
However, no significant differences in baseline blood pressure were observed
PMID 42312814 · one of two readings recorded this
blood glucose response to oral glucose load
no effect
There was no effect of supplementation on blood glucose and plasma insulin responses to an oral glucose load in either the placebo or PS group
PMID 42312814 · one of two readings recorded this
blood pressure
decreases
The db/db mice treated with PS for 4wk exhibited lower blood pressure
PMID 42312814 · one of two readings recorded this
body weight
no effect
In our preclinical study in db/db mice, 4wk of PS supplementation did not alter body weight or epididymal fat weight, nor fasting blood glucose
PMID 42312814 · one of two readings recorded this
brachial artery flow-mediated dilation
no effect
There were no changes noted in either group in other cardiovascular outcomes, including brachial artery FMD, AMBP, or leg BF responses to PLM (Table 2)
PMID 42312814 · one of two readings recorded this
calculated incremental PWV (cPWVinc), femoral and mesenteric arteries
decreases
Similarly, Einc and cPWVinc were lower in isolated femoral and mesenteric arteries from the PS-fed mice
PMID 42312814 · one of two readings recorded this
carotid-femoral pulse wave velocity, SphygmoCor XCEL, humans with T2D, 900 mg/day supplement for 4 wk
Treatment x Time interaction P=0.31; main effect of Time P=0.03; P=0.067 PS group baseline vs final, p = 0.31
Not recorded as a finding: Only the within-arm change and an interaction P are stated in prose; the sentence is a decrease 'approaching statistical significance' with an interaction P of 0.31, so no recordable between-arm direction; node requires path-length convention not stated
In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo).
PMID 42312814 · one of two readings recorded this
carotid-femoral pulse wave velocity (SphygmoCor XCEL) in T2D adults, PS supplement versus placebo
decreases, Treatment x Time interaction P=0.31; main effect of Time P=0.03; P=0.067 PS group baseline vs final, p = 0.31
Not recorded as a finding: decrease is stated with Treatment x Time P=0.31 and no sentence states the between-arm absence; also supplement was 31.1% PS with phosphatidic acid and lysophosphatidylethanolamine absent from placebo
In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo).
PMID 42312814 · one of two readings recorded this
carotid-femoral PWV, baseline vs final
no effect, p = 0.05
In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo)
PMID 42312814 · one of two readings recorded this
carotid-femoral PWV, baseline vs final
decreases, p = 0.067
In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo)
PMID 42312814 · one of two readings recorded this
carotid-femoral PWV, main effect of time
decreases, p = 0.03
In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo)
PMID 42312814 · one of two readings recorded this
carotid-femoral PWV, treatment × time interaction
decreases, p = 0.31
In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo)
PMID 42312814 · one of two readings recorded this
epididymal fat weight
no effect
In our preclinical study in db/db mice, 4wk of PS supplementation did not alter body weight or epididymal fat weight, nor fasting blood glucose
PMID 42312814 · one of two readings recorded this
ex vivo aortic stiffness by AFM
decreases
In addition, in vivo aortic PWV, ex vivo aortic stiffness by AFM, and aortic Einc were lower in PS-treated mice, indicative of reduced aortic stiffness
PMID 42312814 · one of two readings recorded this
F-actin content, mesenteric arteries
decreases
a reduction in F-actin in mesenteric arteries from PS-fed mice
PMID 42312814 · one of two readings recorded this
fasting blood glucose in db/db mice, assay and fasting duration not stated
no effect
Not recorded as a finding: CAT:outcome/fasting-blood-glucose requires venous plasma or serum enzymatic assay after stated overnight fast; the mouse sampling and assay are not stated
In our preclinical study in db/db mice, 4wk of PS supplementation did not alter body weight or epididymal fat weight, nor fasting blood glucose.
PMID 42312814 · one of two readings recorded this
flow-induced dilation, mesenteric arteries
increases
Mesenteric arteries from db/db mice treated with PS demonstrated improved insulin and flow-induced dilation, with no differences in SNP-induced dilation
PMID 42312814 · one of two readings recorded this
human brachial artery FMD, ambulatory blood pressure, plasma lipids, cytokines, plasma nitrite
no effect
Not recorded as a finding: no change reported in agentless sentences that do not name PS; human supplement was a mixed phospholipid product (31.1% PS) against inactive placebo
There were no changes noted in either group in other cardiovascular outcomes, including brachial artery FMD, AMBP, or leg BF responses to PLM (Table 2).
PMID 42312814 · one of two readings recorded this
in vivo aortic pulse wave velocity
decreases
In addition, in vivo aortic PWV, ex vivo aortic stiffness by AFM, and aortic Einc were lower in PS-treated mice, indicative of reduced aortic stiffness
PMID 42312814 · one of two readings recorded this
incremental modulus of elasticity (Einc), femoral and mesenteric arteries
decreases
Similarly, Einc and cPWVinc were lower in isolated femoral and mesenteric arteries from the PS-fed mice
PMID 42312814 · one of two readings recorded this
insulin-induced dilation, cerebral arteries
increases
Insulin-induced dilation was also greater in the cerebral arteries of PS-treated mice
PMID 42312814 · one of two readings recorded this
insulin-induced dilation, isolated mesenteric arteries after overnight sPS
increases
Additionally, overnight incubation with sPS increased insulin-induced dilation, but not SNP-induced dilation, in isolated mesenteric arteries from C57BL/6 mice
PMID 42312814 · one of two readings recorded this
insulin-induced dilation, mesenteric arteries
increases
Mesenteric arteries from db/db mice treated with PS demonstrated improved insulin and flow-induced dilation, with no differences in SNP-induced dilation
PMID 42312814 · one of two readings recorded this
insulin-induced dilation of mesenteric arteries (power-analysis means)
increases
The analysis used means’ responses of 79.40% in PS-treated db/db mice and 43.44% in vehicle-treated db/db mice, with a pooled SD of 18.92%
PMID 42312814 · one of two readings recorded this
insulin receptor alpha content on luminal surface, mesenteric arteries
increases
Importantly, mesenteric arteries from PS-treated db/db mice exhibited more IRα content on the luminal surface, approaching levels observed in wildtype mice
PMID 42312814 · one of two readings recorded this
leg blood flow response to passive leg movement
no effect
There were no changes noted in either group in other cardiovascular outcomes, including brachial artery FMD, AMBP, or leg BF responses to PLM (Table 2)
PMID 42312814 · one of two readings recorded this
load-dependent and structural stiffness, placebo group
no effect
No differences were observed in structural or load-dependent stiffness in the placebo group
PMID 42312814 · one of two readings recorded this
load-dependent arterial stiffness
decreases
Further analysis demonstrated that load-dependent stiffness was reduced in the PS group, while structural-dependent stiffness was unaltered
PMID 42312814 · one of two readings recorded this
medication consumption duration (compliance)
no effect
Individuals in the placebo group averaged 4.04wk of medication consumption, whereas the PS group averaged 4.05wk of medication consumption
PMID 42312814 · one of two readings recorded this
plasma ADAM17 activity
no effect
No differences were observed in plasma lipids, inflammatory cytokines, ADAM17 activity, or plasma nitrite in either group (Table 1)
PMID 42312814 · one of two readings recorded this
plasma inflammatory cytokines
no effect
No differences were observed in plasma lipids, inflammatory cytokines, ADAM17 activity, or plasma nitrite in either group (Table 1)
PMID 42312814 · one of two readings recorded this
plasma insulin response to oral glucose load
no effect
There was no effect of supplementation on blood glucose and plasma insulin responses to an oral glucose load in either the placebo or PS group
PMID 42312814 · one of two readings recorded this
plasma lipids
no effect
No differences were observed in plasma lipids, inflammatory cytokines, ADAM17 activity, or plasma nitrite in either group (Table 1)
PMID 42312814 · one of two readings recorded this
plasma nitrite
no effect
No differences were observed in plasma lipids, inflammatory cytokines, ADAM17 activity, or plasma nitrite in either group (Table 1)
PMID 42312814 · one of two readings recorded this
ROS production, ADAM17-overexpressing endothelial cells
decreases
sPS treatment for 1h attenuated shedding of TNF and ROS production in ADAM17-OE endothelial cells
PMID 42312814 · one of two readings recorded this
SFA blood flow AUC after oral glucose load
increases, p = 0.05
However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation
PMID 42312814 · one of two readings recorded this
SFA blood flow %Δ, main effect of treatment
increases, p = 0.05
However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation
PMID 42312814 · one of two readings recorded this
SFA blood flow %Δ, placebo group
no effect
There were also no changes observed in SFA BF%Δ or SFA Conductance %Δ in the placebo group
PMID 42312814 · one of two readings recorded this
SFA blood flow %Δ, treatment × time interaction
increases, p = 0.06
However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation
PMID 42312814 · one of two readings recorded this
SFA conductance AUC after oral glucose load
increases, p = 0.05
However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation
PMID 42312814 · one of two readings recorded this
SFA conductance %Δ, main effect of treatment
increases, p = 0.05
However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation
PMID 42312814 · one of two readings recorded this
SFA conductance %Δ, placebo group
no effect
There were also no changes observed in SFA BF%Δ or SFA Conductance %Δ in the placebo group
PMID 42312814 · one of two readings recorded this
SFA conductance %Δ, treatment × time interaction
increases, p = 0.1
However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation
PMID 42312814 · one of two readings recorded this
SNP-induced dilation, isolated mesenteric arteries after overnight sPS
no effect
Additionally, overnight incubation with sPS increased insulin-induced dilation, but not SNP-induced dilation, in isolated mesenteric arteries from C57BL/6 mice
PMID 42312814 · one of two readings recorded this
SNP-induced dilation, mesenteric arteries
no effect
Mesenteric arteries from db/db mice treated with PS demonstrated improved insulin and flow-induced dilation, with no differences in SNP-induced dilation
PMID 42312814 · one of two readings recorded this
SNP-induced endothelium-independent relaxation, aortic rings
no effect
PS in db/db mice also abrogated the impaired endothelium-dependent relaxation (i.e., response to ACh) in aortic rings, while endothelium-independent relaxation (i.e., response to SNP) remained unchanged
PMID 42312814 · one of two readings recorded this
sPS binding to recombinant ADAM17
increases
We found that sPS selectively binds to ADAM17-r in a concentration-dependent manner, as demonstrated by SPR
PMID 42312814 · one of two readings recorded this
structural arterial stiffness
no effect
Further analysis demonstrated that load-dependent stiffness was reduced in the PS group, while structural-dependent stiffness was unaltered
PMID 42312814 · one of two readings recorded this
superoxide production (DHE), ADAM17-overexpressing endothelial cells
decreases
ADAM17-OE endothelial cells demonstrated increased O2− production (DHE), and this increase was abrogated by sPS treatment or a TNF-neutralizing antibody
PMID 42312814 · one of two readings recorded this
tail-cuff blood pressure in db/db mice, systolic or diastolic not specified
decreases
Not recorded as a finding: sentence says only blood pressure; no node for unspecified-component rodent blood pressure
The db/db mice treated with PS for 4wk exhibited lower blood pressure.
PMID 42312814 · one of two readings recorded this
TNF-induced ROS production, naive endothelial cells
decreases
Treatment of naive endothelial cells with human recombinant TNF increased ROS production, and this effect was prevented by sPS treatment or Tempol, used as a positive control
PMID 42312814 · one of two readings recorded this
TNF shedding, ADAM17-overexpressing endothelial cells
decreases
sPS treatment for 1h attenuated shedding of TNF and ROS production in ADAM17-OE endothelial cells
PMID 42312814 · one of two readings recorded this
attention, impulsivity, hyperactivity and reaction time on the MOXO continuous performance test; Stroop error rate and correction count, children 10-14 with ADHD or subthreshold ADHD symptoms
increases
Not recorded as a finding: the intervention held more than the compound
The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time.
PMID 42345137 · one of two readings recorded this
attention (MOXO continuous performance test)
unclear
The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time
PMID 42345137 · one of two readings recorded this
cognitive performance (MOXO and Stroop), overall between-group comparison
unclear
Higher-dose phosphatidylserine combined with DHA (PS Plus) yielded superior cognitive benefits compared with placebo and lower-dose formulations
PMID 42345137 · one of two readings recorded this
hyperactivity (MOXO continuous performance test)
unclear
The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time
PMID 42345137 · one of two readings recorded this
impulsivity (MOXO continuous performance test)
unclear
The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time
PMID 42345137 · one of two readings recorded this
MOXO outcomes, placebo, PS Capsule and PS Sachet groups
unclear
The placebo, Capsule, and Sachet groups demonstrated smaller and generally comparable changes
PMID 42345137 · one of two readings recorded this
reaction time (MOXO continuous performance test)
decreases
The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time
PMID 42345137 · one of two readings recorded this
Stroop correction count
decreases
Stroop error rates and correction counts decreased significantly only in the PS Plus group
PMID 42345137 · one of two readings recorded this